Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases

Boehringer Ingelheim

3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, Ontario, Alberta, New Brunswick, Newfoundland and Labrador, Northwest Territories, and through the Non-Insured Health Benefits program for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype (also known as.

Results of the INBUILD clinical trial showed that Ofev slowed the rate of lung function decline by 57% across the overall study population versus placebo.

Read Boehringer Ingelheim press release

Michael Wonder

Posted by:

Michael Wonder